Can-Fite Announces 10-Yr Cancer-Free Survival In Advanced Liver Cancer Patient Treated With Namodenoson

Patient from the Company’s completed Phase II study remains cancer-free and in good health at the ten-year survival milestone

Ramat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that a patient with advanced liver cancer who participated in its completed Phase II study of Namodenoson has reached ten years of overall survival. The patient, whose complete response was previously reported by the Company, remains cancer-free and in good health.

This decade-long survival marks an exceptional individual outcome in advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. Following the Company’s announcement of nine-year survival in November 2025, the patient’s continued well-being adds another year to this remarkable clinical story.